HighTower Advisors
RXRX icon

HighTower Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

HighTower Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,500
Closed -$225 – 3943
2025
Q1 		$225 Buy
+2,500
New +$18.2K ﹤0.01% 3696
2024
Q3 		– Sell
-6,000
Closed -$164 – 3945
2024
Q2 		$164 Buy
+6,000
New +$52.3K ﹤0.01% 3624

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

HighTower Advisors's RXRX Position: Q2 2026 in Review

HighTower Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 79% in Q2 2026, buying an estimated $62.6K and bringing the position to 42,486 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #3589.

HighTower Advisors first reported a position in RXRX in Q1 2024 and has held it in 10 quarters since. The position peaked at $830K in Q4 2024. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • HighTower Advisors held 42,486 shares of Recursion Pharmaceuticals worth $156K as of Q2 2026.
  • HighTower Advisors bought 18,807 Recursion Pharmaceuticals shares in Q2 2026, an estimated $62.6K.
  • Recursion Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3589 holding.
  • HighTower Advisors first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • HighTower Advisors's Recursion Pharmaceuticals position peaked at $830K in Q4 2024.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.